Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease
Amrish Deshmukh,
Miki Yokokawa,
Daniel McBride
et al.
Abstract:BackgroundDofetilide is a class III antiarrhythmic agent approved for the treatment of atrial fibrillation and atrial flutter. Given the efficacy of other class III agents, it has been used off‐label for the treatment of premature ventricular complexes (PVCs) and ventricular tachycardias (VTs).ObjectiveThe purpose of this study was to determine the efficacy and safety of dofetilide for ventricular arrythmias (VAs).MethodsIn this retrospective cohort study, 81 patients (59 men; age = 60 ± 14 years; LVEF = 0.34 … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.